# Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

> **NCT00603824** · PHASE4 · WITHDRAWN · sponsor: **Methodist Healthcare**

## Conditions studied

- Heparin-Induced Thrombocytopenia

## Interventions

- **DRUG:** fondaparinux
- **DRUG:** argatroban or lepirudin

## Key facts

- **NCT ID:** NCT00603824
- **Lead sponsor:** Methodist Healthcare
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-01
- **Primary completion:** 2009-07
- **Final completion:** 2010-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI relocated
- **Last updated:** 2019-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603824, "Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00603824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*